CI-SBPH@EC2610A(19019.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CI-SBPH@EC2610A
19019.HK
News
View More

BOCOM International Holdings Company Sticks to Its Buy Rating for Sino Biopharmaceutical (SBMFF)

BOCOM International Holdings Company analyst maintained a Buy rating on Sino Biopharmaceutical today and set a price target of HK$8.50.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Sino Biopharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of HK$9.14.

Tip Ranks·
HK
01177
-3.35%
Tip Ranks·
HK
01177
-3.35%

New Drug Administration Implementation Regulations Released: Allowing Innovative Drugs to be Produced in Segments, Accelerating the Market Launch of Good Medicines

The State Council has announced the newly revised "Regulations for the Implementation of the Drug Administration Law," which will take effect on May 15, 2026. This is the first comprehensive revision of the regulations in over twenty years. The key points of the revision include: improving the drug registration system, establishing exclusive market periods for pediatric drugs and drugs for rare diseases for the first time (up to 2 years and 7 years respectively), clarifying four new drug expedited approval pathways; strengthening the responsibilities of online drug trading platforms and regulating online drug sales; allowing segmented commissioning of innovative drug production to optimize the industrial supply chain; and shifting the regulatory focus from enterprises to drug marketing authorization holders, enhancing lifecycle supervision

Wallstreetcn·
SZ
159859
-1.00%
SH
588130
-1.08%
SH
589720
-1.55%
Wallstreetcn·
SZ
159859
-1.00%
SH
588130
-1.08%
SH
589720
-1.55%

Sino Biopharmaceutical Reports Positive Phase II Results for Hepatitis B Drug TQA3605

Sino Biopharmaceutical Limited reported positive Phase II trial results for TQA3605, a treatment for chronic hepatitis B. The study involved 122 patients and showed that approximately 90% of those receiving TQA3605 had HBV DNA levels below 20 IU/mL, outperforming the control group on nucleos(t) ide analogues. The safety profile was favorable, with most adverse events being mild. Detailed results will be shared at upcoming international conferences. This news is for informational purposes only and should not be considered financial or legal advice.

Reuters·
SH
512290
-1.55%
SZ
159929
-1.53%
SZ
159837
-1.36%
Reuters·
SH
512290
-1.55%
SZ
159929
-1.53%
SZ
159837
-1.36%

Akeso Updates Contract Manufacturing Arrangement with Supplemental Agreement Expiry Set for 2039

Akeso Inc. has updated its contract manufacturing arrangement with CTTQ-Akeso and others, confirming that the Supplemental Agreement will last until August 29, 2039. The agreement allows for a new contract based on necessity and market conditions. Annual procurement caps for monoclonal antibody products are set considering historical data and market demand, with pricing based on manufacturing costs plus a profit margin. This information is for informational purposes only and should not be considered financial advice.

Reuters·
HK
09926
+0.09%
HK
01177
-3.35%
Reuters·
HK
09926
+0.09%
HK
01177
-3.35%

Sino Biopharma CEO on China's Rapid Clinical Trial Growth

Sino Biopharmaceutical CEO Eric Tse discusses the "survival" necessity of China's rapid clinical trial growth and his open-ended approach to deals in 2026. He speaks to Bloomberg TV's Haslinda Amin on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.Bloomberg videos, provided by MT Newswires

marketscreener·
SZ
159929
-1.53%
SZ
159837
-1.36%
SZ
159859
-1.00%
marketscreener·
SZ
159929
-1.53%
SZ
159837
-1.36%
SZ
159859
-1.00%
Posts
View More
© 2026 Longbridge｜Disclaimer